Anaphylaxis Information

Action Plans 2018

2018 Australasian Society of Clinical Immunology and Allergy (ASCIA) Action Plans

The new 2018 ASCIA Action Plans are now available:

Please note that a student’s current 2017 version of the ASCIA Action Plan remains valid in 2018 if the 'due for review date' is in 2018 or later.

ASCIA Action Plans should be reviewed and reissued when patients are reassessed by their doctor, and each time they obtain a new adrenaline autoinjector prescription, which is approximately every 12 to 18 months.

Changes in 2018

How have the revised ASCIA Action Plans (2018) changed from the previous (2017) versions?

  • They no longer draw attention to the new 3 second hold time, as all the EpiPens with 10 second labels have now expired.

  • To reduce the risk of prescribing or dispensing the incorrect dose of adrenaline autoinjector, ASCIA prescribing guidelines are now included on each plan: (300 mcg for children over 20kg and adults; 150 mcg for children 10-20kg.)

  • The tick instructions have been improved – on personal action plans the medical or nurse practitioner completing the plans should select either “Seek medical help” or “freeze tick and let it drop off”. This is to reduce risk of allergic reactions to ticks as they are removed.

  • As a result of new research data, the following wording has been added to each plan
    - If adrenaline is accidentally injected (e.g. into a thumb) phone your local poisons information centre.
    - Continue to follow this action plan for the person with the allergic reaction.

Generic Action Plans

There is now a generic (not EpiPen specific) Personal ASCIA Action Plan for Anaphylaxis for use with any brand of adrenaline (epinephrine) autoinjector, also available on the ASCIA Website. There is a space to insert specific instructions for the prescribed device in the bottom left corner. This plan can be used if a student is prescribed an adrenaline (epinephrine) autoinjector device other than EpiPen.

Update on other types of adrenaline (epinephrine) autoinjectors:

  • EpiPen remains in Australia. 
  • ‘Emerade’ will not be coming to Australia, now that EpiPen supply is back to normal.
  • ‘Adrenaline Mylan’ is a generic device now available in Australia. It works in exactly the same way as the EpiPen device so the EpiPen trainers can be used to train for both these devices.

The NSW Anaphylaxis Education Program can provide additional support for staff.

Copies of the Action Plans are also available on the Australasian Society of Clinical Immunology and Allergy (ASCIA) website

If you have questions or require clarification about the new ASCIA Action Plans, please contact the NSW Anaphylaxis Education Program on schn-anaphylaxis@health.nsw.gov.au or 02 9845 3501

A Frequently Asked Questions document is also available.